LQDA Oct 2024 10.000 call
| Previous close | 0.5500 |
| Open | 0.5500 |
| Bid | 0.4500 |
| Ask | 0.6500 |
| Strike | 10.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.5500 - 0.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | 5.69k |
ZacksTravere (TVTX) Soars 5.9%: Is Further Upside Left in the Stock?
Travere (TVTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Simply Wall St.With 38% ownership in Liquidia Corporation (NASDAQ:LQDA), institutional investors have a lot riding on the business
Key Insights Significantly high institutional ownership implies Liquidia's stock price is sensitive to their trading...
GlobeNewswireCourt Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today that the United States District Court for the District of New Jersey (District Court) has found that the interference by United Therapeutics Corporation (United Therapeutics) with the launch of generic Treprostinil Injection caused losses in excess of $137M. Treprostinil I
